Rapid and Extensive Expansion in the United States of a New Multidrug-resistantEscherichia coliClonal Group, Sequence Type 1193

2018/06/27 by Veronika L Tchesnokova, Veronika Tchesnokova, Elena Rechkina +28
Biochemistry, Genetics and Molecular Biology · Medicine · #Antibiotic Resistance in Bacteria #Escherichia coli research studies #Urinary Tract Infections Management

paper · pdf · doi:10.1093/cid/ciy525

openalex publication_date 2018/06/27 · openalex created_date 2018/07/10 · openalex updated_date 2026/07/29

Abstract

We describe the rapid and ongoing emergence across multiple US cities of a new multidrug-resistant Escherichia coli clone-sequence type (ST) 1193-resistant to fluoroquinolones (100%), trimethoprim-sulfamethoxazole (55%), and tetracycline (53%). ST1193 is associated with younger adults (age <40 years) and currently comprises a quarter of fluoroquinolone-resistant clinical E. coli urine isolates.

Related

• Tackling drug resistant infection outbreaks of global pandemic Escherichia coli ST131 using evolutionary and epidemiological genomics
• MOLECULAR T YPING AND ANALYSIS OF QUINOLONE-RESISTANT ESCHERICHIA COLI URINARY ISOLATES IN ONCO-HEMATOLOGY PATIENTS AT THE NATIONAL CENTER FOR BONE MARROW TRANSPLANTATION OF TUNISIA
• The role of horizontal gene transfer in the spread of trimethoprim–sulfamethoxazole resistance among uropathogenic Escherichia coli in Europe and Canada
• Detection of integrons and gene cassettes among multidrug resistant (MDR) Escherichia coli uropathogenic strains isolated from clinical specimens in Bushehr
• Prevalence of CTX-M extended-spectrum beta-lactamases and sequence type 131 in Korean blood, urine, and rectal Escherichia coli isolates